Myfembree generic
Myfembree is a drug owned by Myovant Sciences. It contains the active ingredients Estradiol, Norethindrone Acetate, and Relugolix. The drug was first authorized for market use on May 26, 2021.
When will Myfembree generic be available?
Myfembree's patents allow for potential generic competitors to file drug patent challenges from December 18, 2024. The generic versions of Myfembree are expected to be released after May 3, 2038, which is the expiry date of the last patent.
Myfembree uses
Myfembree is prescribed for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. It's also used in the management of moderate to severe pain associated with endometriosis.
Myfembree patent expiration
Myfembree holds a total of six patents. None of these patents have expired yet. The last patent is expected to expire on May 3, 2038. Interested parties can file a drug patent challenge against Myfembree starting from December 18, 2024. Below are the details of the patents: